Evidence map›Paper›PMID 31793076›Full record

ArticleJournal of leukocyte biology2020

IFNγ receptor down-regulation facilitates Legionella survival in alveolar macrophages.

Chao Yang, Daniel S McDermot, Shivani Pasricha, Andrew S Brown, Sammy Bedoui, Laurel L Lenz, Ian R van Driel, Elizabeth L Hartland

Open access · bronzeAbstract read
In one paragraph

Article in Journal of leukocyte biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Chao YangDepartment of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Daniel S McDermotDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Denver, Colorado, USA.
Shivani PasrichaDepartment of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Andrew S BrownDepartment of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Victoria, Australia.
Sammy BedouiDepartment of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Laurel L LenzDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Denver, Colorado, USA.
Ian R van DrielDepartment of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Victoria, Australia.
Elizabeth L HartlandDepartment of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0003-4254-2863
The University of Melbourne · AUUniversity of Colorado Denver · US

Funding

TRAINING PROGRAM IN IMMUNOLOGYT32AI007405 · NIAID · UNIVERSITY OF COLORADO DENVER · PI Laurel L Lenz, Raul Martin Torres · 1991 to 2026
$10.5M
NK cell IL-10 production during bacterial infectionsR01AI131662 · NIAID · UNIVERSITY OF COLORADO DENVER · PI LENZ, LAUREL L · 2017 to 2021
$2.9M
IFNGR Down Regulation as a Host Target for Therapy of Infectious DiseasesR33AI102264 · NIAID · UNIVERSITY OF COLORADO DENVER · PI LENZ, LAUREL L · 2014 to 2016
$1.1M
Myeloid cell IFNGR regulation in persistent viral and secondary bacterial infectionsR21AI140499 · NIAID · UNIVERSITY OF COLORADO DENVER · PI LENZ, LAUREL L · 2018 to 2019
$420k
NIAID NIH HHS R01 AI131662NIAID NIH HHS R21 AI140499NIAID NIH HHS R33 AI102264NIAID NIH HHS T32 AI007405
6 · The paper itself

Abstract

Legionella pneumophila is an opportunistic human pathogen and causative agent of the acute pneumonia known as Legionnaire's disease. Upon inhalation, the bacteria replicate in alveolar macrophages (AM), within an intracellular vacuole termed the Legionella-containing vacuole. We recently found that, in vivo, IFNγ was required for optimal clearance of intracellular L. pneumophila by monocyte-derived cells (MC), but the cytokine did not appear to influence clearance by AM. Here, we report that during L. pneumophila lung infection, expression of the IFNγ receptor subunit 1 (IFNGR1) is down-regulated in AM and neutrophils, but not MC, offering a possible explanation for why AM are unable to effectively restrict L. pneumophila replication in vivo. To test this, we used mice that constitutively express IFNGR1 in AM and found that prevention of IFNGR1 down-regulation enhanced the ability of AM to restrict L. pneumophila intracellular replication. IFNGR1 down-regulation was independent of the type IV Dot/Icm secretion system of L. pneumophila indicating that bacterial effector proteins were not involved. In contrast to previous work, we found that signaling via type I IFN receptors was not required for IFNGR1 down-regulation in macrophages but rather that MyD88- or Trif- mediated NF-κB activation was required. This work has uncovered an alternative signaling pathway responsible for IFNGR1 down-regulation in macrophages during bacterial infection.

Indexed as

AnimalsDown-RegulationInterferon gamma ReceptorInterferon Type ILegionella pneumophilaLegionnaires' DiseaseLungMacrophages, AlveolarMiceMice, TransgenicNF-kappa BReceptors, InterferonSignal TransductionInterferon gamma ReceptorInterferon Type INF-kappa BReceptors, Interferonbacterial lung pathogenIFNγL. pneumophilamacrophages

Identifiers

PMID31793076
PMCPMC8015206
OpenAlexW2992401849

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.